In collaboration with The Thoracic Society of Australia and New Zealand and the Centre of Research Excellence in Pulmonary Fibrosis, PACT runs a webinar series for health professionals.
Watch 2021 webinars on demand now. Register now for our upcoming ATS recap and stay tuned for future webinars.
Health Professional Webinars:
ATS 2022 Pulmonary Fibrosis in a Nutshell – What’s the latest in PF clinical research?
Event Date: Friday 3rd June 2022
Time: 1-2pm AEST
This free webinar will allow health professionals to catch up on the latest in clinical research in pulmonary fibrosis from the May 2022 ATS conference.
ATS is an in person event with no virtual component. We know it is still difficult to travel, so for those not able to make the long trip to San Francisco, PACT and TSANZ are partnering to present this pulmonary fibrosis recap webinar for health professionals to ensure you stay up-to-date!
- Prof Dan Chambers
- A/Prof Yet Khor is an NHMRC Emerging Leadership Fellow at Monash University, a physician at the Austin and Alfred Health Interstitial Lung Disease Services, and the Oxygen Service Lead at Austin Health. Her main research interests include risk prediction and disease burden management in interstitial lung disease.
Planning for implementation using science and strategy
Event Date: Thursday 9th September
Time: 12-1pm AEST
This webinar educated health professionals about the science and strategy of implementation in the context of clinical trials, including insights on planning for future implementation. Implementation is increasingly a focus of funding schemes, meaning that it’s a useful topic for clinical trialists and/or clinician-researchers in pulmonary fibrosis to upskill on!
- Prof Anne Holland
- Prof Natasha A. Lannin (PhD, BSc, GCIS, FAOTA, FOTARA), Professor (Research), Department of Neuroscience, Monash University; and Clinical Chair (Research) – Occupational Therapy, Alfred Health.
- Prof Lannin is a clinical trialist with an extensive research track record in rehabilitation. Working within the Department of Neuroscience at Monash University, she conducts randomised trials investigating the effects of rehabilitation interventions and hybrid implementation studies investigating the translation of trial evidence into clinical practice.
ATS recap – What’s the latest in pulmonary fibrosis clinical research?
Event Date: 11 June 2021
This webinar caught health professionals up on the latest in clinical research in pulmonary fibrosis from the May 2021 ATS conference.
The 2021 ATS was a virtual event and with the time difference between Australia-New Zealand and the USA, joining sessions live was a challenge!
- A/Prof Tamera Corte
- A/Prof Ian Glaspole: A/Prof Ian Glaspole is the head of the Alfred Hospital interstitial lung disease clinic and an adjunct clinical associate professor within the Monash University Faculty of Medicine. His research focuses on interstitial lung disease, and has included numerous clinical trials exploring treatments for idiopathic pulmonary fibrosis, along with other clinical and laboratory based research, principally focused on improving the symptoms and quality of life of sufferers of these rare lung diseases.
New drugs for pulmonary fibrosis – are there any blockbusters around the corner?
Event Date: 30 March 2021
This webinar caught health professionals up on the latest in drug development and clinical trials in pulmonary fibrosis.
It is so heartening to be able to speak optimistically about the future when we see our patients with IPF and other interstitial lung disease in the clinic. Not only do we have two approved drugs, but there are multiple potential breakthrough treatments in clinical development right now, many of them in late phase clinical trials.
- Prof Margaret Wilsher
- Prof Glen Westall is a Consultant Chest Physician, and Head of the Paediatric Lung Transplant Program at the Alfred Hospital, Melbourne. He trained at King’s College, London; the Alfred Hospital, Melbourne and Royal Brompton Hospital, London. Glen oversees the basic scientific research portfolios of the Alfred’s lung transplant and lung fibrosis service. As an academic clinician, he has established a number of translational projects with industry partners that have taken discoveries in basic science to the clinical interface. In particular he has established biorepositories that collect and store both normal lung tissue and fibrotic lungs.
- Prof Dan Chambers is a thoracic and transplant physician with special interests in immunology and interstitial lung disease. Dan’s research focuses on the pathogenesis of lung fibrosis, new diagnostic methods and biomarkers, and therapeutic discovery. His research has been supported by > $15 million in competitive grant funding and he has authored more than 100 research papers. He has been a Principal Investigator for numerous clinical trials of all phases in interstitial and other lung diseases including IPF. Dan is Chair of the Pulmonary Fibrosis Australasian Clinical Trials Network (PACT).
Understanding Pulmonary Fibrosis Clinical Trials
Event date: 20 May 2021
In collaboration with Lung Foundation Australia and the Centre of Research Excellence in Pulmonary Fibrosis, PACT held a clinical trials webinar for consumers on Clinical Trials Day. The webinar provided an insight into Clinical Trials to help you gain an understanding into what it means to participate in research and a Pulmonary Fibrosis clinical trial.
- Prof Dan Chambers is a Thoracic and Transplant Physician and Clinical Professor at the University of Queensland. He cared for many critically ill patients during the Swine Flu epidemic in 2009. His research focuses on severe lung disease and transplantation.